(Adnkronos) - In questo numero:
Diana Bracco riceve dalla Sirm la medaglia d’oro per l’impegno a favore della radiologia
Assemblea Assobìotec: per innovazione serve ricerca nelle biotecnologie e partnership pubblico-privato
Il dermatologo Paro Vidolìn: “Per una corretta protezione dal sole importante usare tanta crema. In laboratorio 2 mg/cm2”
Con DeepHealth una nuova frontiera per radiologia e informatica sanitaria grazie a IA
Ok dell’Aifa alla rimborsabilità del fineròne per malattia renale cronica associata a diabete di tipo 2
Elacestrant nuova terapia in aiuto di pazienti con carcinoma mammario
Congresso Sirm: grazie all’IA radiologia medica innovativa e all’avanguardia
Davanzo della Còmasin, con tele-supporto all’allattamento al seno + 25% il tasso a 3 mesi dal parto, ed l’effetto dura fino a 6 mesi
Le Car T ide-cel e liso-cel sono ora rimborsabili rispettivamente per il mieloma multiplo e il linfoma diffuso a grandi cellule B
Anmvi, il progetto culturale One Health dei veterinari nelle scuole compie 10 anni. Erogate oltre 6.000 ore di lezioni a 33.000
A seguire lo Speciale Salus Tv dal titolo: Giornata mondiale della sclerodermìa, cinque azioni per migliorare la qualità di vita dei pazienti
Diana Bracco riceve dalla Sirm la medaglia d’oro per l’impegno a favore della radiologia
Assemblea Assobìotec: per innovazione serve ricerca nelle biotecnologie e partnership pubblico-privato
Il dermatologo Paro Vidolìn: “Per una corretta protezione dal sole importante usare tanta crema. In laboratorio 2 mg/cm2”
Con DeepHealth una nuova frontiera per radiologia e informatica sanitaria grazie a IA
Ok dell’Aifa alla rimborsabilità del fineròne per malattia renale cronica associata a diabete di tipo 2
Elacestrant nuova terapia in aiuto di pazienti con carcinoma mammario
Congresso Sirm: grazie all’IA radiologia medica innovativa e all’avanguardia
Davanzo della Còmasin, con tele-supporto all’allattamento al seno + 25% il tasso a 3 mesi dal parto, ed l’effetto dura fino a 6 mesi
Le Car T ide-cel e liso-cel sono ora rimborsabili rispettivamente per il mieloma multiplo e il linfoma diffuso a grandi cellule B
Anmvi, il progetto culturale One Health dei veterinari nelle scuole compie 10 anni. Erogate oltre 6.000 ore di lezioni a 33.000
A seguire lo Speciale Salus Tv dal titolo: Giornata mondiale della sclerodermìa, cinque azioni per migliorare la qualità di vita dei pazienti
Category
🗞
NewsTranscript
00:00In this number, Diana Bracco receives from SIRM the gold medal for the commitment in favor of radiology.
00:17Assemblea Sobiotech for Innovation and Research in Biotechnology and Private Public Partnership.
00:25Dermatologist Paro Vidolin, for a correct protection from the sun, it is important to use a lot of cream.
00:31In the laboratory, 2 mg per square centimeter.
00:34CondiPelt, a new frontier for radiology and health informatics, thanks to artificial intelligence.
00:41And again, OK Day Life for the reimbursability of finerone, for chronic kidney disease associated with type 2 diabetes.
00:49Elasestrand, new therapy in the help of patients with mammary carcinoma.
00:54Congresso SIRM, thanks to artificial intelligence, innovative medical radiology is at the forefront.
01:01Davanzo della Comazin, with telesupport for breastfeeding, plus 25% the 3-month rate from birth and the effect lasts up to 6 months.
01:11The IDECEL and ISOCEL cards are now refundable respectively for multiple myeloma and lymphoma spread to large B cells.
01:20ANVI, the One Health cultural project of veterinarians in schools, turns 10 years old.
01:25Delivered over 6,000 hours of lessons to 33,000 children.
01:29Follow Special Salus TV with the title World Scleroderma Day, 5 actions to improve the quality of life of patients.
01:42For the extraordinary dedication and passion with which he has contributed to innovation, to the development of radiology worldwide.
01:49For the tireless commitment and the long-term vision that have not only elevated the standards of the discipline,
01:54but also improved in a tangible way the quality of the diagnostic procedures of millions of patients.
01:59And for his professional excellence and his pioneering spirit, Dr. Diana Bracco, President and CEO of the Bracco Group,
02:06leader in imaging diagnosis, was awarded the SIRM gold medal,
02:11on the occasion of the opening ceremony of the first joint congress of the scientific societies of the radiological area.
02:18It was undoubtedly exciting to be in front of a classroom so full of people of that level,
02:24because they are all scientists, they are all doctors, they are all radiologists.
02:29So this was exciting.
02:31The motivations that have been given to me are exciting,
02:36which say that we are committed for a lifetime to this sector,
02:41to this sector to achieve what we call an improvement in the quality of life of people.
02:48That is our goal, that we pursue and that the SIRM pursues.
02:53So there is a convergence of visions.
02:56The Italian Society of Medical Radiology and Intervention
02:59defines the work of Diana Bracco as an Italian triumph and beacon of inspiration for the scientific society.
03:05Dr. Diana Bracco is a pioneer in the field of imaging diagnosis
03:10and the means of contrast in imaging diagnosis.
03:13So Bracco has always accompanied mine and will accompany the future generations of radiologists.
03:20For this reason, it seemed necessary for us as a scientific society
03:24to recognize her great vision and her commitment to the development of our discipline.
03:36Competitiveness, the node of research, the role of the enterprise.
03:39It was the claim of the convention held in the framework of the annual assembly of ASU Biotech FederChimica
03:45held in Rome at the auditorium of the Tecnica di Confindustria.
03:49An initiative that had as a focus of work the role of the private sector
03:53in supporting the progress of research and the challenges of contemporary society
03:57in accompanying scientific evolution.
04:00An appointment that allowed to highlight the important role that biotechnologies have
04:05in helping the European Union to modernize the primary sector and industry
04:09because, as evidenced in the document produced by the European Commission,
04:12biotechnologies and bioproductions are among the most promising technologies of this century.
04:18Biotechnologies are enabling technologies that can be used for health,
04:23for the environment, for agriculture, for industry.
04:26A few months ago, in March, the European Union published a manifesto
04:31in which it highlights the importance of these technologies for the whole century ahead.
04:37So soon we will also have a request from the European Union to move as a country.
04:43We have great opportunities.
04:45We must, in some way, make a system,
04:48try to understand what are the obstacles that we must solve in every area
04:52to be able to be competitive as a country.
04:55We must start from the assumption that an idea must become a solution for citizens and patients.
05:01And to have the idea we need young people who can do research
05:06and start this path of the idea that becomes the solution.
05:11It is fundamental that research is sufficiently financed and encouraged,
05:17especially for young people,
05:19who must then look at research not only from the point of view of scientific publications,
05:24but also to create companies.
05:26Today we have had the evidence that in all sectors it is necessary
05:29that young researchers see as a way to do something concrete,
05:34to put research into practice,
05:36to become protagonists also in the industrial part of solutions for citizens.
05:41In the course of the initiative, institutional representatives,
05:45scientists, companies, employees and associations of category
05:48alternated on the stage to assess the potential and value of biotechnologies.
05:52A strategic asset for Italy today and tomorrow,
05:55but also an opportunity to develop knowledge of the economy and well-being.
05:59For this reason, during the initiative,
06:01it was possible to emphasize the importance of research,
06:04especially in the field of pharmaceuticals, for the development of the biotech drug.
06:09Research, especially in the biotechnological field, is very expensive,
06:13but it often promises the definitive cure of chronic diseases
06:18or genetic diseases that were previously incurable.
06:21Sometimes it also promises the prevention of the emergence of a pathology.
06:27This, of course, opens up roads from both an economic and social point of view.
06:34Roads that will have to see an adaptation of the system,
06:39also in the form of payment,
06:41which sees these cures as an investment and not as an immediate cost.
06:46The Biotech drug can be a resource for the country
06:50because we have all the structures to become potential great producers.
06:57We have all the expertise that we must try to maintain in Italy.
07:04Biotech can finally be the opportunity to reverse the flow of brains
07:10from Italy to other countries,
07:13but try to attract them here, at least recall ours.
07:21With the arrival of summer, the sun returns to dominate,
07:24with temperatures that rise to 40 degrees or more
07:26and that push to escape the heat of the city,
07:28to lighten the clothing and to find a refrigerator in the sea or lake areas
07:32where it is possible to take refreshing baths.
07:34To defend the skin from problems such as burns and prevent pathologies,
07:38even serious ones, such as melanoma,
07:40it becomes essential to use the right sunscreens
07:42and follow some simple recommendations.
07:44As explained by dermatologist Andrea Paro Vidolin,
07:46head of the Center for Photodermatology of the Israeli Hospital of Rome,
07:50against skin aging and photocarcinogenesis,
07:52photo protection plays an essential role.
07:55There is a topical photo protection, so the protective creams.
07:59Let's remember that you have to apply a lot of product,
08:03in the laboratory 2 mg per square centimeter,
08:07and then renew the application often,
08:09at least every hour is absolutely essential.
08:12It is also essential to reapply it after the bath,
08:14because even if they are water resistant,
08:16it is certainly important to reapply them,
08:18and pay attention to the reflective surfaces,
08:21so the sand, the water, the grass, but also the cement,
08:25has a reflective power,
08:27so you are not at risk of ultraviolet rays.
08:31And to tan properly,
08:33it is very important to avoid hypothetical shortcomings.
08:36You have to pay attention to self-tanners,
08:39they do not protect us from the sun
08:41and you always have to put a high protection factor.
08:46Or, for example, tanning lamps,
08:48this is absolutely to be avoided,
08:50and every dermatologist does not recommend doing it,
08:53but the people who ask for it,
08:56it is absolutely not a way to prepare the skin for the sun,
09:01absolutely not, you have to be very careful,
09:03even in that case, let's say,
09:05use very high protection factors.
09:07If the weather is cloudy, there is a false sense of security,
09:10even more you have to protect yourself from ultraviolet rays.
09:14In addition to the topical photo protection in sunscreens,
09:17very important is also the systemic one, for the mouth.
09:20Surely food can be important,
09:22but the amount of active ingredients in antioxidants
09:26is absolutely much higher,
09:28so with integrators, natural substances,
09:31taken for systemic, for the mouth,
09:33that help to defend from ultraviolet rays,
09:37from photoaging or from photocarcinogenesis,
09:39and they act in synergy with the topical photo protection,
09:42so with the lipsticks.
09:44Naturally, they must be taken in the two or three months
09:47prior to exposure to ultraviolet rays.
09:54Favor an early identification,
09:56reliable and efficient in the areas of mammary health,
09:59pulmonary, cerebral and prostatic,
10:02is based on this intention,
10:04the integrated portfolio of solutions supported by AI,
10:07presented by DeepHealth,
10:09global leader in radiology and health informatics,
10:12solutions focused on an advanced operating system,
10:15which with the support of artificial intelligence,
10:18unifies the data generated
10:20along the clinical and operational work process
10:23for all professionals involved in the radiological continuum.
10:26Why do we want to do this?
10:28Because we want to try to increase
10:30access to the patient's clinical care.
10:33Let's think of screening plans,
10:36to perform a screening plan at the lung level,
10:39in Italy we should scan 2.5 million patients per year.
10:44How can we do this if we don't have a support?
10:47These are the areas we want to invest in,
10:50try to enable the health system
10:53to perform large volumes of patients
10:56and therefore have a patient,
10:59access to the service greater than what they have now.
11:03This usually, especially in the screening part,
11:06which is fundamental for us,
11:08will certainly have a better prognosis for the patient.
11:11Among the collaborations launched in Italy by DeepHealth,
11:14also the one with the ASL Roma2,
11:17for the screening of neurodegenerative diseases
11:20through the Brain AI software,
11:22certified in the National Plan of Diseases,
11:25which played a key role in the study
11:28conducted at the ASL Roma2
11:30to promote early diagnosis of cognitive disorders
11:33in the geriatric population.
11:36The interesting aspect is that in these people
11:39with subjective disorders or initial cognitive disorders,
11:43the fate can be different.
11:46Some remain stable,
11:49others progress towards more serious disorders,
11:52others even regress.
11:55If we use these three combinations,
11:58we can understand the people
12:01who need more comprehensive interventions,
12:04that is, multidisciplinary interventions.
12:07Cognitive training, support for the family,
12:10the need to change lifestyles.
12:13This study has been interesting in my opinion
12:16because it brings together different personalities
12:19and has brought together professionals
12:22who came from totally separate environments.
12:25Artificial intelligence has the ability
12:28to give a mathematical evaluation
12:31that does not interfere with what could be
12:34the subjective interpretation of a pathological
12:37or morphological aspect of a patient,
12:40thus allowing to monitor at zero time
12:43what will be the evolution of the disease.
12:46The possibility to preventively identify
12:49certain morphological or biological alterations
12:53of the patient allows to accelerate
12:56the diagnostic times and subsequently
12:59also the healing times.
13:02In this sense, in cognitive diseases,
13:05we have to evaluate in a preventive way
13:08what could be the evolution
13:11of a cognitive decline process,
13:14according to the radiological aspects
13:17that we find in magnetic resonance tests
13:21that are carried out in a specific way.
13:29In Italy, 40% of diabetic patients
13:32have a chronic kidney disease
13:35that leads to gradual kidney damage,
13:38hypertension and cardiovascular problems
13:41to reach the terminal stage of the disease,
13:44i.e. dialysis or transplantation.
13:47Patients with a chronic kidney disease
13:50associated with type 2 diabetes
13:53have a new therapeutic option
13:56that shows an anti-inflammatory and anti-fibrotic effect
13:59in the kidney, heart and vases.
14:02It was mentioned at the press conference
14:05about the future absence of dialysis by Bayer.
14:08In addition to the inhibitor acids,
14:11the antagonist of angiotensin receptors
14:14is the antagonist of the steroid
14:17that has an anti-fibrotic,
14:20anti-proteinuric and anti-progressive effect
14:23of the kidney disease.
14:26It is a very important weapon
14:29that we are about to add
14:32to what we already have.
14:39Fine Renone is the first non-steroidal
14:42non-steroidal drug of corticosteroids receptors.
14:45The difference of this new receptor antagonist
14:48is that it has a completely different structure.
14:51This determines,
14:54following the bond with the receptor
14:57of these hormones,
15:00stimuli at the level of cytokines,
15:03of pro-inflammatory and pro-fibrotic substances
15:06of the inhibitor type.
15:10The Fidelio Registration Study
15:13has shown that Fine Renone
15:16is able to slow down the progression
15:19of kidney damage in patients
15:22at very high risk
15:25and at high risk,
15:28in particular patients with a clearance
15:31between 25 and 75 with an albuminuria,
15:34an ACR between 30 and 5,000 mg.
15:38With Fine Renone, Bayer enters
15:41a new therapeutic area,
15:44that of nephrology.
15:47It is very important
15:50because we have a history of research
15:53in various therapeutic areas
15:56and I think that our cardiovascular partnership
15:59is known to everyone
16:02and today we finally start
16:05to offer a concrete solution
16:08to the scientific community
16:11but above all to the Italian patients
16:14who need it the most.
16:17An update course has been held in Rome
16:20on the fight against carcinoma mammary ER positive
16:23HIR2 negative advanced metastatic
16:26with ESR1 mutations,
16:29which has seen the participation
16:32of new therapeutic and effective endocrine options
16:35that could help the population of patients
16:38affected by this pathology.
16:41Elastestrant is a new drug,
16:44a new antihormonal that belongs
16:47to the category of oral SERD
16:50that stands for selective degraders
16:53of the estrogen receptor and in practice
16:56it acts by inhibiting the function
17:00of the endocrine system
17:03and thus avoiding the time of chemotherapy.
17:06This endocrine therapy can now be administered
17:09in women who have escaped endocrine therapy.
17:12It is a change in the global approach
17:15to patients with positive hormonal receptors
17:18because the time of chemotherapy that frightens our patients
17:21is many months away
17:24from the start of the metastasis
17:28During the course, the topic of tolerance
17:31and the effectiveness of this new oral therapy has been addressed
17:34useful to counteract breast cancer.
17:37Oral therapy by patients is always a very well accepted therapy
17:40because it can be done at home.
17:43In the case of Elastestrant we have an optimal toxicity profile
17:46with not many side effects
17:49and therefore it is a treatment indicated in patients
17:52both with a good performance status and with a performance status
17:55because it does not require specific therapeutic presidia
17:58to tampon the adverse events of toxicity.
18:01The aim of the ECM course was therefore
18:04to bring into discussion the most relevant and critical aspects
18:07in the definition of the optimal treatment algorithm
18:10in Italy of patients
18:13underlining that the SR1 mutations
18:16are a well-known driver of resistance to standard endocrine therapies
18:19and so far difficult to treat.
18:22It is a mutation that arises as a phenomenon of resistance
18:25under the inhibition of hormone therapy
18:28so patients who have this mutation
18:31have a lower response to traditional hormone therapy
18:34but instead a better response to Elastestrant.
18:37The research work carried out by an Italian company
18:40has been of great importance
18:43which has contributed to the realization of the new Elastestrant therapy.
18:46Thanks to the commitment of the Minarini group
18:49through a compassionate use program
18:52we have given the opportunity to access this therapy
18:55in a few months to more than 100 patients
18:58and others will have access to it in the coming weeks.
19:01We do not stop there
19:04but the commitment of the group
19:07is to continue to develop new molecules
19:10both in the carcinoma mammary but also in other solid types
19:13in addition to the commitment we have in hematology for several months.
19:20Early and extremely accurate diagnoses
19:23with non-invasive tests to be able to intervene on the pathologies
19:26when they are still at the initial stages
19:29customization of treatments based on the needs of the person
19:32to guarantee better results with less side effects
19:35and even provision of success in a precise way
19:38is what is possible to obtain thanks to the artificial intelligence
19:41applied to medical radiology.
19:44This was discussed during the second day of the 51st National Congress
19:47of the Italian Society of Medical and Interventional Radiology
19:50in Milan until Sunday, June 23.
19:53Artificial intelligence has also opened an unthinkable diagnostic front
19:56until a few years ago
19:59the exploration of digital data.
20:02Every information that derives from TAC images
20:05and magnetic resonance
20:08actually has a numerical data
20:11that is absolutely unexplored by the human eye.
20:14The computer, in particular the artificial intelligence
20:17allows us to identify
20:20new parameters that are extremely useful
20:23for the diagnosis
20:26an increasingly early and precise diagnosis
20:29and above all to give new criteria for the evaluation
20:32of the effectiveness of the therapy
20:35increasingly early.
20:38Technological innovation in radiology does not only concern devices
20:41as in the case of ultrasound with contrast media
20:44and computerized tomography
20:47but also the procedures of interventional radiology.
20:50The President of the 51st CIRM Congress illustrates the pathologies
20:53that at the moment can benefit more from such innovations.
20:56Certainly all the primitive and secondary tumors
20:59of the liver, the primitive and secondary tumors of the lung
21:02the tumors of the kidney
21:05we are now for a while
21:08doing treatments of pancreas tumors
21:11can be treated with metastasis
21:14also for the palliative purpose
21:17and above all what we can say
21:20is that interventional radiology allows
21:23minimally invasive treatments
21:26that certainly improve the quality of life
21:29and bring the patient much faster to functional recovery.
21:32It makes its entrance in the field of radiology
21:36valuable not only for future health professionals
21:39that thanks to it can practice
21:42procedures and exams but also for patients.
21:45Augmented reality helps the patient
21:48for example in the acceptance of the exam
21:51today several systems have been studied
21:54and also produced in clinics
21:57to immerse the patient in a virtual reality
22:00before or during the execution of a radiological exam
22:03reducing in this way the anxiety of the exam
22:06we think of magnetic resonance exams
22:09that today can last more than 20 minutes
22:12and that are practically impossible to perform in claustrophobic patients
22:15or in pediatric patients
22:18the possibility of immersing oneself in a virtual reality can help the patient.
22:25An increase of 25% of the exclusive breastfeeding rate
22:28three months after birth
22:32has a positive effect
22:35and can last up to six months
22:38this is the main data from a recent study
22:41conducted by the Italian Society of Neonatology
22:44on a champion of nurses and doctors of Italian neonatology
22:47that has shown how, although it is more difficult
22:50the communication between health workers and mothers
22:53and breastfeeding telecommunication is appreciated by families
22:56also allowing a greater participation of parents
22:59however, the development of telecommunications in the last 150 years
23:02has been impressive, both in terms of devices
23:05and for the type of connectivity
23:08during the Covid-19 pandemic, the use of telemedicine has increased enormously
23:11based on these experiences
23:14the SIN has made and distributed a position statement
23:17on breastfeeding telesupport
23:20coordinated by Dr. Riccardo D'Avanzo
23:23President of the Breastfeeding Commission of the Italian Society of Neonatology
23:26the SIN has been the first to support breastfeeding remotely
23:29especially in the first three months of life
23:32when doubts about the ability
23:35to be able to meet the nutritional needs of the baby
23:38are greater
23:41but good words are not enough
23:44we must also try to understand
23:47when it comes to an unmotivated fear
23:50or when the baby is actually
23:53available for breastfeeding
23:56and the criteria that the mother
23:59sets for the attention of health workers
24:02are the most varied, the most different
24:05from the behavior of the baby
24:08from the crying of the baby
24:11from the shortening of time between one breastfeeding and the other
24:14in reality, it is growth
24:17the criterion that informs us the most
24:21on the fact that the milk production
24:24is going well
24:27and that the baby is growing in an adequate way
24:30despite the fact that in 2022
24:33legislative decrees were issued on telemedicine
24:36and that the PNRR itself recognizes telemedicine
24:39a central role in the reorganization of health care
24:42the experiences of breastfeeding telesupport
24:45once the pandemic emergency passed
24:48were unfortunately stopped in much of the health structures
24:51ignoring the great value that the World Health Organization
24:54attributes to preventive interventions in the area of infant maternal health
24:57the WHO suggests
25:00to breastfeed exclusively for 6 months
25:03if the mother and the baby want it
25:06and if he grows in an adequate way
25:09but it is in the first weeks of life
25:12that this help is needed
25:15breastfeeding can be in the presence
25:18but sometimes the hospital
25:21is not able to give an appointment
25:24in the short term
25:27for problems that the mother
25:30often perceives as serious
25:33or as urgent
25:36let's say that
25:39phone calls
25:42can be a filter
25:45to decide
25:48which families
25:51to connect
25:54with a video call
25:57or with a computer
26:00connection
26:03sometimes, however,
26:06even though telemedicine is effective
26:09to maintain breastfeeding
26:12especially in the first months of life
26:15sometimes the problem is not solved
26:18and these may be the women
26:21who will be brought to the ambulance
26:24in person in the hospital
26:30The Italian Pharmaceutical Agency has given free rein
26:33to the reimbursement of two cell therapies with CAR T
26:36Ide-Cell for the treatment of multiple myeloma
26:39and Iso-Cell for lymphoma spread to large B cells
26:42The therapies are suitable for adult patients
26:45with recurrent and refractory disease
26:48who have already received at least three previous therapies
26:51CAR T represents the evolution of immunotherapy
26:54Immunotherapy has as a foundation
26:57to stimulate the immune system of the person
27:00to fight tumor disease
27:03In the case of CAR T, instead, it is personalized
27:06that is, the cells of the single patient are taken
27:09and are engineered
27:12to make them work against the specific antigen
27:15present in the patient's disease
27:18Ide-Cell represents today
27:21the only therapeutic option for patients affected by multiple myeloma
27:24who have not responded to the three first-line therapies
27:27that have shown refractory disease to the last line of therapy
27:30and that, in the absence of treatment with Ide-Cell
27:33would have a survival expectancy of less than a year
27:36Having available a therapy that exceeds
27:39the resistance mechanisms, which is able
27:42to offer responses in about 80%
27:45of a population of patients
27:48who have taken any other therapeutic alternative
27:51and to offer a survival expectancy
27:54which is about two years
27:57With a good quality of life
28:00because the therapy we are talking about
28:03is a therapy with a single infusion
28:06certainly represents a great success
28:09but above all a great therapeutic possibility
28:12that can be offered to our patients
28:15New cases of lymphoma in Italy
28:18are more than 14,000 every year and the first line of treatment
28:21cures over 50% of patients
28:24Those who instead do not respond to the first-line therapy
28:27and are affected by the most aggressive forms of lymphoma
28:30the one spread to large B cells, the primitive one of the mediastinum
28:33and the follicular one of grade 3
28:36today Ide-Cell represents a potentially curative treatment
28:39The revolution is precisely in this
28:42this group of patients for whom we had
28:45extremely limited therapeutic prospects
28:48with almost no chance of healing
28:51today they are able to obtain
28:54certainly amazing results
28:57If we look at the study
29:00that was done with Iso-Cell
29:03we can see how
29:06the percentage of complete and partial remissions
29:09increases by 75%
29:12but above all
29:15there are more than 50% of patients
29:18who obtain a complete remission
29:21many of these complete remissions remain permanent
29:24thus giving the idea of a definitive healing
29:32The health of animals is closely connected
29:35to ours and to that of the whole planet
29:38and it is therefore necessary to transfer this concept
29:41and make it understandable also to the children of the primary school
29:44and with this goal that ANVI
29:47has celebrated the first 10 years
29:50of a didactic project called CONZAMPA
29:53to the lesson of One Health
29:56and carried on thanks also to the contribution of MSD Animal Health
29:59The pet is taking on a completely different social role
30:02from that of 10 years ago
30:05it is an integral part of our family
30:08it brings us joy and well-being
30:11and therefore it is our duty to raise awareness
30:14of what it means to have it as part of the family
30:17take care of it, but not only for our happiness
30:20but also for its well-being and health
30:23how to do it in a better way
30:26if not thanks to the intervention of veterinary doctors
30:29in collaboration with teachers
30:32and go and talk to the students of the primary schools
30:35and their families
30:38therefore focus on the new generations
30:41The role of the veterinary doctor
30:44takes a central position in our society
30:47let's say that it is being rediscovered
30:50because some aspects of our profession
30:53such as food safety
30:56if all the products of animal origin
30:59that add to the quality of life
31:02and the quality of life of the animals
31:05have to be taken into account
31:08if the products of animal origin
31:11that are added to our table are healthy
31:14we owe it to the veterinary doctor
31:17the veterinary doctors also
31:20thanks to a project that has been going on for 14 years
31:23are present in the schools
31:26therefore in the primary schools
31:29the veterinarian teaches the children
31:32what is the right relationship with animals
31:35From 2014 to today the ANVI study group
31:38has trained more than 200 veterinarians
31:41who in turn have delivered more than 6,000 hours of lessons
31:44to 33,000 students in more than 1,000 school buildings
31:47Among the topics discussed are biodiversity in the animal world
31:50the cycle of life of domestic animals
31:53the importance of the animal in child development
31:56The response from the schools is positive
31:59with teaching students who ask to continue
32:02We are in the guiding lines of civic education
32:05a subject on which we focus a lot
32:08for the growth of our children
32:11respect for animals
32:14for the ecosystem, for the general environment
32:17so this was a novelty
32:20because it had never been specifically planned
32:23an attention to animals
32:26The aim now of the association is to extend the project
32:29to secondary schools
32:32collaborating with the Ministry of Education and Health
32:35to recognize the veterinarian
32:38his new role as an educator at World Health
32:46There are about 30,000 people in Italy
32:49affected by systemic sclerosis
32:52autoimmune pathology, rare, chronic and progressive
32:55that affects the cuticle, blood vessels
32:58lungs and kidneys
33:01and the ligament and skeletal muscle
33:04making them unable to perform their function
33:07On the occasion of the World Scleroderma Day
33:10the Italian World Scleroderma Foundation
33:13and the Italian Group for the Fight against Scleroderma
33:16on Friday, June 21, they promoted in Rome
33:19two appointments to focus on the disease
33:22The first, titled New Challenges for Systemic Sclerosis Patients
33:25was held in Montecitorio
33:28in the Queen's Hall
33:31The second, dedicated to the pathology
33:34was a scientific conference
33:37titled New Therapeutic Horizons
33:40and was held in the Rapacis Auditorium
33:43with IWS-FI, GILS-ODV-ETS
33:46and Spring Systemic Sclerosis Progression Investigation
33:49with the support of the European Scleroderma Trials and Research Group
33:52and the Italian Society of Rheumatology
33:55and the Italian Society of Internal Medicine
33:58as explained by the President of the Italian World Scleroderma Foundation
34:01Marco Amatucci Cerinic
34:04The conference highlighted in particular the most innovative treatments available today
34:07through the administration of monoclonal therapies
34:10of antifibrotic therapy and of the innovative treatment with CAR-T cells
34:13What is important to understand is that with these therapies
34:16we are able to block the progression of the disease
34:19especially, not only from the point of view of the skin
34:22but also of the internal organs
34:25the lung first
34:28and we have so-called immunosuppressive therapies
34:31that greatly reduce inflammation
34:34and today we have another group of drugs
34:37which are the very useful antifibrotic
34:40because together with the immunosuppressive anti-inflammatories
34:43they are able to block the evolution towards fibrosis
34:46and this is why today the antifibrotics
34:49have become, together with the immunosuppressive
34:52the reference therapies, also in combination
34:55to be able to prevent our patients from losing their quality of life
34:58with the loss of the function
35:01which is linked to the fibrosis of the organ
35:04And of the two events, the five actions necessary
35:07to improve the quality of life of patients in Italy
35:10a greater awareness of the doctors of general medicine
35:13a greater awareness of the symptoms that can make the disease suspicious
35:16and send these patients to specialized centers as soon as possible
35:19centers on the national territory of which a network must be created
35:22to reach an early diagnosis that allows to block the pathology
35:25maintaining at best the quality of life of the patient
35:28and thus also beating the costs of medical management
35:31which is serious on the national health service
35:34the support of a diagnosis-therapeutic-assistive path
35:37homogeneous throughout the territory
35:40and the promotion of basic research
35:43and clinical experimentation
35:46which in an extremely complex pathology such as scleroderma
35:49represents an important challenge for the future
35:52the rooms are full of representatives of the institutions
35:55who participated in the first appointment
35:58promoted by Luciano Ciocchetti, vice-president of the 12th Social Affairs Commission of the Chamber
36:01There is still a need to do more
36:04in taking care of the patients
36:07in the definition of the training
36:10of the doctors of general medicine
36:13of the territorial specialists
36:16because clearly being a rare disease
36:19it has difficulties in being recognized immediately
36:22very important then continues Ciocchetti
36:25to enhance the work that local health companies do throughout the country
36:28in a hospital-territorial connection
36:31that is able to accompany the patients
36:34especially the most serious
36:37because this disease also causes difficulties in social life
36:40in everyday life
36:43in respiratory difficulties
36:46so objectively there is still a lot to do
36:49a work has been set up
36:52initiatives like this also help to strengthen
36:55the need to do more
36:58and to reorganize the territorial system of the city
37:04on the part of the associations that represent the needs of the patients
37:07then emerges the need to increase the sensitivity
37:10of the public opinion on the symptoms and effects
37:13on the daily life of scleroderma
37:16instituting multidisciplinary diagnostic-therapeutic courses
37:19and facilitating access to oxygen to those suffering from scleroderma
37:22not only lung fibrosis
37:25a complication that, as explained by Ilaria Galetti
37:28vice-president of the Federation of European Scleroderma Association
37:31on health and pathology
37:34both on the quality of life of the patient
37:37on the street you do not see many people with oxygen
37:40why?
37:43because once the so-called pump is finished
37:46there is no longer the possibility of recharging it
37:49you are left without a life-saving drug
37:52what we would like is a simple thing
37:55the possibility of recharging the pump
37:58with a life-saving drug
38:01in pharmacies
38:04it is a drug that should be dispensed in pharmacies
38:07also because I would like to remind you
38:10that the European Constitution provides for the free circulation
38:13of people on the territory
38:16of the EU countries
38:19but this is not happening
38:22not even within your municipality
38:26this was our last news
38:29to contact us you can write to
38:32health at dncronos.com
38:35thanks for following us and see you next episode